---
title: "NP49425 Generic and Biosimilar Transition Medicines"
ocid: "ocds-r6ebe6-0000807501"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000807501"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000807501.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000807501.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)"
published: "2026-03-30"
---

# NP49425 Generic and Biosimilar Transition Medicines

Buyer: THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)  
Current stage: Award  
OCID: ocds-r6ebe6-0000807501

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000807501)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000807501.json)

## Summary

The Common Services Agency, widely known as NHS National Services Scotland (NSS), has completed the tender process for the "NP49425 Generic and Biosimilar Transition Medicines" procurement, aimed at supplying these medications to NHS Scotland. The procurement falls under the goods category, specifically classified under the CPV code 33600000, indicating pharmaceutical products. The location for delivery spans all entities constituted under the National Health Service (Scotland) Act 1978 within the UK region UKM. The procurement process followed an open procedure method, marked by key dates, including a start date for the award period on 18 December 2025, and the tender submission closing on 22 September 2025. The associated contract carries a total estimated value of GBP 234,969,011, to be executed over a variable duration across individual product lines, with provisions for optional extensions.

This tender presents a significant opportunity for large-scale pharmaceutical suppliers, particularly those specialising in generic and biosimilar medicines, to expand their operations by partnering with a major public health authority in Scotland. The framework agreement, structuring the tender into multiple lots for different medicines, such as cytokine modulators and cancer medicines, provides diverse entry points for suppliers. Companies with strong supply chain capabilities and compliance with quality assurances like BS EN ISO 9001 and MHRA guidelines stand well-positioned to benefit from this substantial procurement. The involvement of community benefit initiatives further enhances opportunities, allowing suppliers to engage more deeply with local communities through the NHS Scotland's Community Benefits Gateway.

## Notice

Supply of generic and biosimilar transition medicines to NHS Scotland.

### Lot Information

Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)

Supply of generic cand biosimilar transition medicines to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per line to six (6) Framework Participants. Full details of Goods and volumes can be found within the ITT (Invitation to Tender) documents.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cytokine Modulators (Omalizumab)

Supply of cytokine modulators (omalizumab) to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines

Supply of gastrointestinal, endocrine, blood, and multiple sclerosis medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Denosumab (Osteoporosis) and Ferric Carboxymaltose

Supply of denosumab (osteoporosis) and ferric carboxymaltose to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Apremilast

Supply of apremilast to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-seven (27) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cardiovascular and Respiratory Medicines

Supply of cardiovascular and respiratory medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Nintedanib

Supply of nintedanib to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cancer Medicines (Group 1)

Supply of cancer medicines (group 1) to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cancer Medicines (Group 2)

Supply of cancer medicines (group 2) to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Psychiatry and Neurology Medicines

Supply of psychiatry and neurology medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of seventeen (17) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552801 |
| Notice type | OJEU - F20 - Modification Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 30 Mar 2026 |
| Submission deadline | 22 Sep 2025 |
| Future notice date | Not specified |
| Award date | 18 Dec 2025 |
| Contract period | 1 Feb 2026 - 30 Sep 2028 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £234,969,011 |
| Lots value | £234,969,011 |
| Awards value | Not specified |
| Contracts value | £128,207,480 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS) |
| Locality | EDINBURGH |
| Post town | Edinburgh |
| Postcode | EH12 9EB |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM1 East Central Scotland |
| ITL 3 | TLM13 City of Edinburgh |
| Local authority | City of Edinburgh |
| Electoral ward | Drum Brae/Gyle |
| Westminster constituency | Edinburgh South West |
| Delivery location | TLM Scotland |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 37 |
| Supplier names | ACCORD HEALTHCARE; AMAROX; AMGEN; AOP ORPHAN; BIOCON PHARMA; BROWN AND BURK; CELIX PHARMA; CELLTRION HEALTHCARE UNITED KINGDOM; CHIESI; CST PHARMA; DR FALK PHARMA; DR REDDY'S LABORATORIES (UK; FERRING PHARMACEUTICALS; FRESENIUS KABI; GEDEON RICHTER; GLENMARK PHARMACEUTICALS EUROPE; JANSSEN-CILAG; LUPIN HEALTHCARE; MERCURY PHARMA GROUP; MERCURY PHARMACEUTICALS; MSN LABS; PERENNIAL PHARMA; PFIZER; ROCHE PRODUCTS; SAMSUNG BIOEPIS; SANDOZ; SERB; STADA UK - THORNTON & ROSS; TAKEDA; TEVA; THERAMEX HQ; VIATRIS UK HEALTHCARE; VIFOR PHARMA; WOCKHARDT; ZENTIVA; ZENTIVA PHARMA; ZYDUS PHARMACEUTICALS |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 30 Mar 2026 at 00:00 - AwardUpdate - OJEU - F20 - Modification Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552801
- 19 Dec 2025 at 00:00 - Award - OJEU - F3 - Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=DEC546134
- 4 Sep 2025 at 00:00 - TenderUpdate - OJEU - F14 - Corrigendum - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP538562
- 21 Aug 2025 at 00:00 - Tender - OJEU - F2 - Contract Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG537425

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG537425
  NP49425 Generic and Biosimilar Transition Medicines - Supply of generic and biosimilar transition medicines to NHS Scotland.
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=DEC546134
  NP49425 Generic and Biosimilar Transition Medicines - Supply of generic and biosimilar transition medicines to NHS Scotland.
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552801
  NP49425 Generic and Biosimilar Transition Medicines

## Notice URLs

- http://
- http://www.nss.nhs.scot/browse/procurement-and-logistics
- http://www.publictendersscotland.publiccontractsscotland.gov.uk
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000807501
- https://scotcourts.gov.uk/the-courts/sheriff-court/about-sheriff-courts
- https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000807501. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000807501.json.